ライフサイエンスコーパス: vitamin K1

1 quinone, a late biosynthetic intermediate of vitamin K1.

2 re fed a diet supplemented with warfarin and vitamin K1.

3 of the oxidized primary donor and a reduced vitamin K1.

4 ticoagulation clinic examined the effects of vitamin K1 100 mug daily on INR variability and found no

5 in-like CXXC center involved in reduction of vitamin K1 2,3-epoxide (Vit.K>O).

6 Changes in plasma phylloquinone and vitamin K1-2,3-epoxide were no different in the two grou

7 1.3+/-9.0 nmol x h/L for the lipid group for vitamin K1-2,3-epoxide).

8 vitamin K deficiency and minidose warfarin, vitamin K1-2,3-epoxide, PIVKA-II, and percentage underca

9 serial measurements of plasma phylloquinone, vitamin K1-2,3-epoxide.

10 Finally, vitamin K1 absorption was compared between wild-type mic

11 A significant interaction between low vitamin K1 and antihypertension medication use was detec

12 rew on brucella blood agar supplemented with vitamin K1 and hemin and on brucella laked blood agar su

13 brucella laked blood agar supplemented with vitamin K1 and hemin.

14 idant, we report here the novel finding that vitamin K1 and K2 (menaquinone-4) potently inhibit gluta

15 cella agar supplemented with 5% sheep blood, vitamin K1, and hemin.

16 ction monitoring mode with deuterium-labeled vitamin K1 as an internal standard.

17 e absorption and transport of phylloquinone (vitamin K1) by plasma lipoproteins.

18 ignal can be directly attributed to A-1, and vitamin K1 can be assigned as this PSI acceptor.

19 CAC progression for subjects with low serum vitamin K1 compared with subjects without extreme CAC pr

20 A serum vitamin K1 concentration was considered low at <1.0 nmol

21 ti-inflammatory factors of the diet, such as vitamin K1, could play a protective role.

22 nge was +5 +/- 20 Agatston units (AU) in the vitamin K1 group (n = 40) and +44 +/- 13 AU in the place

23 nd the direct carboxylase inhibitor 2-chloro-vitamin K1 have no effect on the protective function of

24 ive, and specific analytical method to study vitamin K1 in fruits and vegetables.

25 c properties of provitamin A, vitamin E, and vitamin K1 in the gas phase for the first time.

26 To examine the association between dietary vitamin K1 intake and the risk of incident cataracts in

27 rticipants in the highest tertile of dietary vitamin K1 intake had a lower risk of cataracts than tho

28 Dietary vitamin K1 intake was evaluated using a validated food f

29 Low phylloquinone (vitamin K1) intake is a potential risk factor for bone f

30 mice compared with wild-type mice, but their vitamin K1 intestinal content remained unchanged.

31 he ability to convert dietary phylloquinone (vitamin K1) into menaquinone-4 (vitamin K2) and store th

32 of warfarin and administering 2.5 mg of oral vitamin K1 is a reliable, safe, and inexpensive way to r

33 e of our primary analysis suggests low serum vitamin K1 is associated with greater CAC progression, t

34 liver to preserve coagulation function when vitamin K1 is limiting.

35 In 68 of 71 patients (96%), oral vitamin K1 lowered the INR from between 5.0 and 10.0 to

36 es of warfarin, administering 2.5 mg of oral vitamin K1, measuring the INR after 24 to 48 hours, and

37 Treatment with large doses of oral vitamin K1, often over months to years, to maintain a ne

38 d agar (the last three media did not contain vitamin K1 or hemin).

39 Vitamin K1 (phylloquinone) intestinal absorption is thou

40 Despite earlier acceptance of oral vitamin K1 (phytonadione) for the treatment of excessive

41 anar with the ring) conformations of UQ- and vitamin K1- radicals is estimated to be sufficiently lar

42 needed to determine whether improving serum vitamin K1 reduces CAC progression, especially in hypert

43 pective study and two prospective studies of vitamin K1 supplementation (with doses ranging from 100

44 by using post hoc per-protocol analyses of a vitamin K1 supplementation trial.

45 as to determine the effect of phylloquinone (vitamin K1) supplementation on CAC progression in older

46 of the preferential distribution of dietary vitamin K1 to the liver to preserve coagulation function

47 s with SR-BI and CD36 significantly enhanced vitamin K1 uptake, which was subsequently decreased by t

48 id transport via SR-BI) blocked up to 85% of vitamin K1 uptake.

49 roteins is dependent on formation of reduced vitamin K1 (Vit.K1H2) in the endoplasmic reticulum (ER),

50 approach for the simultaneous estimation of vitamin K1 (VK1) and heparin via cascaded channel multia

51 High intake of dietary vitamin K1 was associated with a reduced risk of catarac

52 Apical transport of vitamin K1 was examined using Caco-2 TC-7 cell monolayer

53 Low serum vitamin K1 was significantly associated with CAC progres

54 Serum phylloquinone (vitamin K1) was measured in 296 participants with extrem

55 Hypertension medication users with low serum vitamin K1 were more likely to have extreme CAC progress